GSK
GSK
840 hedge funds and large institutions have $12.4B invested in GSK in 2020 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 270 increasing their positions, 320 reducing their positions, and 62 closing their positions.
47% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 62
32% more call options, than puts
Call options by funds: $94.9M | Put options by funds: $71.7M
3% more funds holding
Funds holding: 817 → 840 (+23)
4% more capital invested
Capital invested by funds: $11.9B → $12.4B (+$520M)
0.12% less ownership
Funds ownership: 5% → 4.87% (-0.12%)
16% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 320
25% less funds holding in top 10
Funds holding in top 10: 16 → 12 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$190M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$167M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$85.1M |
| 4 |
Two Sigma Advisers
New York
|
+$83.2M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$51.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$172M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$159M |
| 3 |
Renaissance Technologies
New York
|
-$104M |
| 4 |
Dodge & Cox
San Francisco,
California
|
-$103M |
| 5 |
Morgan Stanley
New York
|
-$49.5M |
GSK Hedge Fund Activity: Q2 2020 in Review
840 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2020, worth a combined $12.4B — up 4.4% from $11.9B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new GSK positions and 62 closed out — a net gain of 29 holders — while 270 added to existing stakes and 320 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $190M. The largest seller was Boston Partners, cutting an estimated $172M.
- 840 institutional investors held GSK (GSK) as of Q2 2020, up from 817 in Q1 2020.
- Funds reported $12.4B of GSK stock for Q2 2020, up 4.4% quarter-over-quarter.
- 91 funds opened new GSK positions in Q2 2020 and 62 closed out, a net change of +29 holders.
- The largest GSK buyer in Q2 2020 was Capital Research Global Investors, an estimated $190M added.
- The largest GSK seller in Q2 2020 was Boston Partners, an estimated $172M sold.
Based on aggregated 13F filings for Q2 2020.